7th Meeting of the European Hereditary Tumour Group (EHTG)

Friday, Sept 29th – Sunday, Oct 1st 2023
Vilnius, Lithuania

Final Program
Invitation

7th Meeting - Vilnius, Lithuania

Dear Members, Friends, Affiliates and Sponsors,

We are delighted to invite you to the 7th annual EHTG meeting in beautiful Vilnius, Sept. 29 to Oct. 1 2023. Our lively program includes selected hot and controversial topics, debates, new interactive formats and our workshop day with in-depth scientific discussions. Join us in person or online during the hybrid event!

Days 1 (Friday) and 3 (Sunday) will follow the plenary format without parallel sessions. Day 2 (Saturday) is our dedicated working group (WG) day, with three parallel groups. The submitted abstracts were allocated to be presented in the different WGs and the highest rated abstracts will also be presented in a separate “best abstracts” session (day 1).

Additionally, our meeting dates are back-to-back with the European Society of Coloproctology’s annual conference on Sept 27-29; we envisage that bilateral synergistic effects will result from this collaborative meeting. On Thursday, Sept. 28, we will host the ESCP-EHTG joint symposium at the ESCP venue. On Saturday, an additional EHTG-ESCP workshop is scheduled for clinicians interested in surgical management of hereditary predisposition syndromes.

After last year’s successful launch, our 7th meeting provides an open platform for patient societies and networking. Continuing our international collaboration in this field, we welcome and encourage patients and patient societies to join us in person or virtually in Vilnius.

Vacation in beautiful Vilnius? Why not spend a few days before or after the meeting? Our venue, The Panorama Hotel, is located in Vilnius’ old town, only 1.5km from the Gate of Dawn. The hotel’s top-floor lounge gives guests spectacular panoramic city views. The historic Gediminas Tower and Town Hall Square can be reached within a 15-minute walk. Or head out further afield with the bus and train stations only a 3-minute walk from the Hotel.

Visit www.ehtg.org for more information and contact gs007@ehtg.org for all organisational queries. If you have any suggestions, please get in touch with any of the board members.

We are genuinely excited to see you in Vilnius!

Sincerely, your EHTG Board Members
Content

Invitation ..................................................... 2-3
Organisation .............................................. 5
Overview day 1 ............................................. 6
Overview day 2 ............................................. 7
Overview day 3 ............................................. 8
Day 1 – Friday, September 29th
(wh)y-EHTG Session ........................................ 10
Opening Remarks / Plenary Session 1 ................. 10
Big Debate .................................................. 11
Panel discussion .......................................... 11
Best of Abstracts .......................................... 12-13
Welcome Reception ....................................... 13
EHTG Nurses Meeting ..................................... 14
y-EHTG Social Networking .............................. 13/14
Day 2 – Saturday, September 30th
Open PLSD Meeting ....................................... 15
Working Group 1 .......................................... 16-17
Working Group 2 .......................................... 18-19
Working Group 3 .......................................... 19-20
Working Group 4 .......................................... 20-21
Working Group 5 .......................................... 22
Working Group 6 .......................................... 23
Working Group 7 .......................................... 24-25
Working Group 8 .......................................... 26
Working Group 9 .......................................... 27
CMMRD Session .......................................... 28
EHTG-ESCP international Surgery Day “ISTOIC” . . 30-31
Conference Dinner ........................................ 29
Day 3 – Sunday, October 1st
EHTG Business Meeting ................................... 32
WG Reporting Back Session and Collaborative Studies . 32
Hot Topics .................................................. 32
Networking with patients and their organizations .... 32
Pathology and clinical data in childhood ............... 32
Late Breaking Abstracts ................................... 33
Newly emerging technologies .......................... 33
Farewell ................................................... 33
Faculty ..................................................... 34-41
Sponsors .................................................... 42
Imprint ..................................................... 42

Organisation

Board Members: Aysel Ahadova (Germany)
Peter Bauerfeind (Switzerland)
John Burn (United Kingdom)
Mev Dominguez Valentin (Norway)
Fiona Laloo (United Kingdom)
Gabriela Moslein (Germany)
Pål Møller (Norway)
Julian Sampson (United Kingdom)
Toni Seppala (Finland)
Rolf Sijmons (The Netherlands)
Sanne ten Broeke (The Netherlands)

Program Committee: Mev Dominguez Valentin (Norway)
Aysel Ahadova (Germany)
Elizabeth Half (Israel)
Kelly Kohut (UK)
Neil Ryan (UK)
Sanne ten Broeke (The Netherlands)
Laura Thomas (UK)
Ingrid Winship (Australia)

Secretariat: Gabriele Sponholz
gs007@ehtg.org
+49-160-8459502
D-65207 Wiesbaden (Germany)

Location: Panorama Hotel, Vilnius, Lithuania
https://panoramahotel.lt/reservation@panoramahotel.lt
Only direct booking

Registration: Only online via www.ehtg.org

Registration Fee: See online via www.ehtg.org

Certification: We have applied for certification by EACCME and expect the same certification as last year (6/8/5)
### Meeting Overview

**Day 1 – Friday, September 29th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td>Registration</td>
</tr>
<tr>
<td>09:00 - 11:00</td>
<td>(wh)y-EHTG Session</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:30 - 13:30</td>
<td>Plenary Session 1</td>
</tr>
<tr>
<td>13:30 - 14:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:30 - 15:15</td>
<td>Big Debate</td>
</tr>
<tr>
<td>15:15 - 16:15</td>
<td>Panel discussion Gynaecological Surveillance</td>
</tr>
<tr>
<td>16:15 - 16:45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:45 - 17:45</td>
<td>Best of Abstracts</td>
</tr>
<tr>
<td>17:45 - 18:15</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td>17:45 - 18:15</td>
<td>EHTG Nurses Meeting</td>
</tr>
<tr>
<td>20:00 +</td>
<td>y-EHTG Social Networking</td>
</tr>
</tbody>
</table>

**Day 2 – Saturday, September 30th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td>Open PLSD Meeting</td>
</tr>
<tr>
<td>09:00 - 11:00</td>
<td>Parallel Working Groups 1 - 3</td>
</tr>
<tr>
<td>09:00 - 11:00</td>
<td>EHTG-ESCP international Surgery Day “iSTOIC”*</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:30 - 13:30</td>
<td>Parallel Working Groups 4 - 6</td>
</tr>
<tr>
<td>11:30 - 13:30</td>
<td>EHTG-ESCP international Surgery Day “iSTOIC”*</td>
</tr>
<tr>
<td>13:30 - 14:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:30 - 16:30</td>
<td>Parallel Working Groups 7 - 9</td>
</tr>
<tr>
<td>14:30 - 16:30</td>
<td>EHTG-ESCP international Surgery Day “iSTOIC”*</td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>CMMRD Session</td>
</tr>
<tr>
<td>19:30 +</td>
<td>Conference Dinner</td>
</tr>
</tbody>
</table>

*International Surgical Group Operating on Inherited colorectal Cancer*
Meeting Overview

Day 3 – Sunday, October 1st

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td>EHTG Business Meeting</td>
</tr>
<tr>
<td>09:00 - 10:00</td>
<td>WG Reporting Back Session and Collaborative Studies</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:30 - 11:30</td>
<td>Hot Topics</td>
</tr>
<tr>
<td>11:30 - 12:30</td>
<td>Networking with patients representatives and organizations</td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>Pathology and clinical data in childhood</td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td>Late Breaking Abstracts</td>
</tr>
<tr>
<td>14:00 - 14:45</td>
<td>Newly emerging technologies</td>
</tr>
<tr>
<td>14:45 - 15:00</td>
<td>Farewell</td>
</tr>
</tbody>
</table>

We look forward to your personal attendance, but also offer the meeting with all sessions live online.
**Scientific Program**

**Day 1 – Friday, September 29**

**08:00-09:00** | Registration

**09:00-11:00** | (wh)y-EHTG Session  
*Chairs: Sanne Bajwa-ten Broeke (Netherlands)  
Demetra Georgiou (UK)  
Aysel Ahadova (Germany)*

Top abstract 1  
Co-design of the Lynch Choices patient resource including cultural translation to improve equity, diversity and inclusion  
8'+2'  
Kelly Kohut (UK)

Top abstract 2  
The immune profile of Lynch syndrome-associated colorectal adenomas pinpoints the main determinants of immune activation  
8'+2'  
Lena Bohaumilitzky (Germany)

Top abstract 3  
Co-evolution of mismatch repair loss and the immune response in Lynch syndrome  
8'+2'  
Ottilie Swinyard (UK)

09:30-10:00 | Y-EHTG Dragons Den for new proposals

10:00-11:00 | Y-EHTG show & tell

11:00-11:30 | Coffee Break

11:30-13:30 | Opening remarks  
*Gabriela Moeslein (Germany)*

**Plenary Session 1**  
*Chairs: Ann-Sofie Backman (Sweden)  
Matthias Kloor (Germany)  
Zohar Levi (Israel)*

Clinical Translation of Cancer Immunoprevention  
15'+5'  
*Shizuko Sei (USA)*

Evolving therapy of MMR-deficient CRC  
15'+5'  
*Frank A. Sinicrope (USA)*

EHTG initiative: harmonization of global Lynch syndrome guidelines  
15'+5'  
*Giulia Cavestro (Italy)*

13:30-14:30 | Lunch

14:30-15:15 | Big Debate – Urological Surveillance  
*Chairs: Elizabeth Half (Israel)  
Richard Gallon (UK)  
Tanya Bisseling (The Netherlands)*

Urological surveillance in Lynch syndrome an opportunity for early detection? Possible and necessary/not an option and is unnecessary  
15’  
Marco Moschini (Italy)

15’  
Ulla Nordstroem (Denmark)

15:15-16:15 | Panel discussion  
**Gynaecological Surveillance**  
*Is there a role for gynaecological surveillance in Lynch syndrome/HBOCS?*  
*Chairs: Neil Ryan (UK)  
Emma Crosbie (UK)  
Anja Wagner (The Netherlands)*

Ovarian cancer prevention in high-risk groups  
7' + 3’  
Robert Fruscio (Italy)

Universal germline testing and/or dMMR tumor screening among all endometrial cancer patients  
7' + 3’  
Heather Hampel (USA)

Gynaecological surveillance in high-risk groups in The Netherlands  
7' + 3’  
Ellis Eikenboom (The Netherlands)

30’ | Panel Discussion
Scientific Program
Day 1 – Friday, September 29th

16:15-16:45 | Coffee Break

16:45-17:45 | Best of Abstracts

Cancer in patients with Familial adenomatous polyposis - a nationwide Danish cohort study with matched controls.
Anne Marie Jelsig (Denmark)

Whole genome sequencing findings in families tested negative based on family history -
Mev Dominguez (Norway)

Experiences from direct provider-mediated cascade-testing in Lynch syndrome families – the Danish model.
Lars Lindberg (Denmark)

Outcomes of Lynch syndrome endometrial cancer surveillance in a nation-wide cohort.
Anja Wagner (The Netherlands)

Comprehensive molecular profiling of patient-derived tumor organoids uncovers in vitro drug sensitivities of sporadic and hereditary colorectal cancers.
Erdogan Pekcan Erkan (Finland)

Guidelines in „plain language“ for patients affected by Lynch syndrome. Abstract 50
Katlijn Sanctorum (Belgium)

Germline variants in PARP1 as potential cause of colonic polyposis in adults. Abstract 20
Laura Valle (Spain)

Detection of microsatellite instability using plasma-derived extracellular vesicle DNA – a new perspective for tumor surveillance in Lynch syndrome?
Lena Bohaumilitzky (Germany)

The optimal endoscopic surveillance in hereditary diffuse type gastric cancer; random or targeted biopsy taking?
Tanya Bisseling (The Netherlands)

Impact of Pathogenetic MMR Genotypes on Systemic Metabolomic Signatures.
Tiina Jokela (Finland)

An Exploration of the Somatic and Germline Mutational Profiles of Early-Onset Colorectal Cancer Based on Two UK Patient Cohorts.
Penelope Edwards (UK)

Colibactin mutational signatures in NTHL1 Tumor Syndrome, MUTYH Associated Polyposis and unexplained polyposis patients.
Diantha Terlouw (The Netherlands)

17:45-18:15 | Welcome Reception

20:00 + | y-EHTG Social Networking
**Scientific Program**

**Day 1 – Friday, September 29th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30-20:00</td>
<td>EHTG Nurses Meeting</td>
</tr>
</tbody>
</table>
| 18:30-18:35   | Welcome and introduction  
Laura Monje-Garcia (UK)  
Mechelle Loughrey (Ireland) |
| 18:35-18:45   | Summary of role and objectives of the EHTG Committee Member  
Laura Monje-Garcia (UK)  
Mechelle Loughrey (Ireland)  
Celia Diez de los Rios (Spain) |
| 18:45-19:15   | Snapshot of current hereditary cancer nursing services  
Mechelle Loughrey (Ireland)  
Laura Monje-Garcia (UK)  
Celia Diez de los Rios (Spain) |
| 19:15-19:25   | Opportunity for attendees to discuss their service  
Open |
| 19:25-19:35   | Question time  
Open |
| 19:35-19:45   | Service improvement +/- site visits,  
Research collaboration opportunities  
Laura Monje-Garcia (UK)  
Mechelle Loughrey (Ireland) |
| 19:45-20:00   | Brainstorming session regarding future meetings board membership etc.  
Open |
| 20:00 +       | y-EHTG Social Networking                                                                  |

**Scientific Program**

**Day 2 – Saturday, September 30th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>Open PLSD Meeting</td>
</tr>
</tbody>
</table>
| 08:00-08:10   | Overview of the PLSD  
Mev Dominguez-Valentin (Norway) |
| 08:10-08:25   | The four Lynch syndromes  
- where are we?  
- Time since last colonoscopy as surrogate for RTC?  
- Polyps and CRC incidences?  
Pål Møller (Norway) |
| 08:25-08:30   | Studies on gynaecological surveillance?  
Neil Ryan (UK) |
| 08:30-08:35   | PRS and panel testing?  
Mev Dominguez-Valentin (Norway) |
| 08:35-08:40   | Call for new data: PLSDv6  
Mev Dominguez-Valentin  
- Including polyp data?  
- Including immunotherapy?  
- Including more genes?  
Mev Dominguez-Valentin (Norway) |
| 08:40-08:55   | General discussion  
All |

---
## Scientific Program

### Day 2 – Saturday, September 30th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-11:00</td>
<td>Joint ESCP-EHTG Hereditary Surgery Symposium</td>
</tr>
<tr>
<td></td>
<td>See page 30-31 for details</td>
</tr>
<tr>
<td>09:00-11:00</td>
<td>Parallel Working Groups 1-3</td>
</tr>
<tr>
<td></td>
<td><strong>Group 1 – Gastroenterology, Surveillance and Microbiome</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Elizabeth Half (Israel)</td>
</tr>
<tr>
<td></td>
<td>Peter Bauerfeind (Switzerland)</td>
</tr>
<tr>
<td></td>
<td>Martina Cavestro (Italy)</td>
</tr>
<tr>
<td></td>
<td>The role of genotoxic gut bacteria in hereditary and sporadic colorectal cancer</td>
</tr>
<tr>
<td></td>
<td>Dan Buchanan (Australia)</td>
</tr>
<tr>
<td>15’ + 5’</td>
<td>Perceptions and Attitudes towards Faecal Immunochemical Testing (FIT)</td>
</tr>
<tr>
<td></td>
<td>as a Provisional Modality for Risk-Stratified Colonoscopy in a Lynch syndrome Patient Population</td>
</tr>
<tr>
<td></td>
<td>Kevin Monahan (UK)</td>
</tr>
<tr>
<td>6’ + 2’</td>
<td>The optimal endoscopic surveillance in hereditary diffuse type gastric cancer; random or targeted biopsy taking?</td>
</tr>
<tr>
<td></td>
<td>Tanya Bisseling (The Netherlands)</td>
</tr>
<tr>
<td>6’ + 2’</td>
<td>The diagnostic yield of colonoscopic surveillance following resection of early-age onset colorectal cancer (EOCRC).</td>
</tr>
<tr>
<td></td>
<td>Husam Al Maliki (UK)</td>
</tr>
<tr>
<td>6’ + 2’</td>
<td>Four decades of endoscopic surveillance in Lynch syndrome reveals a slightly higher complication rate - a retrospective cohort study on safety and adverse events</td>
</tr>
<tr>
<td></td>
<td>Alexander Frank (Sweden)</td>
</tr>
</tbody>
</table>

### Efficacy and Outcomes of Pancreatic Cancer Screening Program in CAPS-Eligible versus non-CAPS-Eligible populations: A Single Center Study

**Erez Hasnis (Israel)**

15’ + 5’

- Duodenal disease phenotype in MUTYH-associated polyposis: updated findings from an international prospective study.
  **Laura Thomas (UK)**

15’ + 5’

- The impact of a novel expert multidisciplinary meeting for the management of hereditary colorectal cancer risk.
  **Avani Varde (UK)**

15’ + 5’

- Quality of Endoscopic Surveillance in Lynch Syndrome Patients at a Highly Specialized Center in Sweden - Interval, Adenoma Detection, and Cleanliness.
  **Sophie Walton Bernstedt (Sweden)**

15’ + 5’

- Distinct gastric phenotype in patients with SMAD4-associated Juvenile Polyposis Syndrome: A nationwide study
  **Anne Marie Jelsig (Denmark)**

15’ + 5’

- Risk Factors and Clinical Characteristics of Young-Onset Gastric Cancer vs. Late-Onset Gastric Cancer. a case-case-study
  **Marta Puzzono (Italy)**

15’ + 5’

- Colibactin mutational signatures in NTHL1 Tumor Syndrome, MUTYH Associated Polyposis and unexplained polyposis patients
  **Diantha Terlouw (The Netherlands)**

15’ + 5’

- Characterizing unique microbiome alterations in Lynch syndrome within the druze community in Israel
  **Elizabeth Half (Israel)**
Scientific Program

Day 2 – Saturday, September 30th

09:00-11:00  Group 2 – Carcinogenic mechanisms and pathways / early onset cancers / novel associations

Room Plantaria

Chairs: Richarda de Voer (The Netherlands)
Matthias Kloor (Germany)
Laura Thomas (UK)

Arsenic-free diet can decrease the risk of cancers in females from families with aggregation of breast cancers
Jan Lubinski (Poland)

Additive effects of selenium and arsenic can be considered for effective diagnosis of significantly lower cancer risk in brca1 carriers on arsenic free diet
Jan Lubinski (Poland)

Mathematical guidance for the interpretation of PCR-based MSI diagnostics
Alexander Zeilmann (Germany)

Mathematical modeling of Lynch syndrome cancer development - A multi-scale view from the DNA over the tissue level to clinical translation
Saskia Haupt (Germany)

Co-evolution of mismatch repair loss and the immune response in Lynch Syndrome
Ottilie Swinyard (UK)

The associations of circulating microRNAs and lifestyle with cancer risk among Finnish Lynch syndrome carriers
Tero Sievänen (Finland)

Leveraging whole exome sequencing of Lynch syndrome associated primary colorectal cancer to illuminate the aetiology of β-catenin dependent subtype.
Kalle Hokkanen (Finland)

Impact of Pathogenetic MMR Genotypes on Systematic Metabolomic Signatures
Tiina Jokela (Finland)

Scientific Program

Day 2 – Saturday, September 30th

09:00-11:00  Group 3 – Families with inherited cancer/ patient organizations

Room Aeris

Chairs: Nicola Reents (Germany)
Simone Widhalm (Germany)
Kelly Kohut (UK)

Guidelines in „plain language“ for patients affected by Lynch syndrome
Katlijn Sanctorum (Belgium)

Co-design of patient information leaflets for cancer genetics
Julie Young (UK)

Co-design of the Lynch Choices patient resource including cultural translation to improve equity, diversity and inclusion
Kelly Kohut (UK)

The National Nursing Workshops: Adapting Delivery and Content to Increase Awareness of Lynch syndrome.
Amy Sanderson (UK)

Diagnosis and management of Lynch Syndrome in an Irish Context: An Advanced Nurse Practitioner (ANP) Led Service
Mechelle Loughrey (Ireland)
Scientific Program

Day 2 – Saturday, September 30th

8’ + 3’
Mandy Darbyshire (UK)
Melissa Cambell-Kelly (UK)

The NHS English National Lynch syndrome transformation project: Setting up the Regional Lynch syndrome Expert Network for the North Thames Genomic Medicine Service Alliance (GMSA)
8’ + 3’
Anna Koziel (UK)

A questionnaire-based assessment of holistic clinical care for Lynch syndrome linked to regular colonoscopic surveillance episodes
8’ + 3’
Penelope Edwards (UK)

Identifying barriers to colonoscopic screening in asymptomatic first-degree relatives of patients with hereditary CRC in Pakistan – A pilot study.
8’ + 3’
Raza Sayyed (Pakistan)

Finding the missing 95%: The English National Lynch syndrome transformation project
8’ + 3’
Kevin Monahan (UK)

11:00-11:30 Coffee Break

11:30-13:30 EHTG-ESCP international Surgery Day “iSTOIC”
See page 30-31 for details

11:30-13:30 Parallel Working Groups 4-6
11:30-13:30 Group 4 – Epidemiology of hereditary cancer
Chairs: Sigurdís Haraldsdóttir (Iceland)
Heather Hampel (USA)
Mev Dominguez (Norway)

Integrated Germline-Somatic Analysis: Research Insights from the MSK-IMPACT Initiative
30’ + 6’
Zsofia Stadler (USA)

Scientific Program

Day 2 – Saturday, September 30th

The rate of ATM pathogenic variants (PVs) in a series of unselected Israeli Pancreatic Cancer Patients
9’ + 3’
Rakefet Chen-Shtoyerman (Israel)

Colorectal cancer incidences in carriers with and without colorectal adenomas
9’ + 3’
Pål Møller (Norway)

Colorectal cancer incidences in path_MLH1 and path_MSH2 carriers in three continents
9’ + 3’
Pål Møller (Norway)

Cancer in patients with Familial adenomatous polyposis - a nationwide Danish cohort study with matched controls
9’ + 3’
Anne Marie Jelsig (Denmark)

Whole genome sequencing findings in families tested negative based on family history
9’ + 3’
Mev Dominguez Valentin (Norway)

Incidence of adenomatous polyps and colorectal cancer in Dutch patients with PMS2-associated Lynch syndrome undergoing surveillance: a prospective cohort analysis
9’ + 3’
Katarina Andini (The Netherlands)

Prevalence of familial pancreatic cancer and inherited cancer syndromes in pancreatic cancer patients in Iceland 2000-2021
9’ + 3’
Ásthildur Rafnsdóttir (Iceland)
Scientific Program

Day 2 – Saturday, September 30th

11:30-13:30

Group 5 – BY INVITATION ONLY:
Brainstorming on the harmonization of global Lynch syndrome guidelines and initiation of the process. Step one: identification of the discrepancy-based questions to be addressed
Chairs: Giulia Cavestro (Italy)
Alessandro Mannucci (Italy)
Gabriela Möslein, Germany

We are planning a harmonization of the global guidance for Lynch syndrome.
The topic is the initiative to harmonize the different evidence-based guidelines for Lynch syndrome and elaborate a global consented guideline based on the newest available literature and – of course – expert guidance via a Delphi process for questions without sufficient evidence. As you may be aware, EHTG has published previously a sequence of guidelines for Lynch syndrome (LS), first based on expert opinion only and in 2021, after an extensive process of literature review and Delphi consensus the first “dynamic” guideline for LS in BJS (T. T. Seppälä et al., European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender, British Journal of Surgery, Volume 108, Issue 5, May 2021, Pages 484–498, https://doi.org/10.1002/bjs.11902)

We have invited global experts in order to discuss and initiate the process.
Invited individuals will receive the link beforehand.

11:30-13:15

Group 6 – Personalized medicine and targeted prevention
Chairs: Anja Wagner (The Netherlands)
Nadir Arber (Israel)
Frank A. Sinicrope (USA)

Beyond Checkpoint Blockade for dMMR/MSI-High Cancers - Advances and Challenges
Kai-Keen Shiu (UK)

A significant proportion of advanced colonic neoplasia could have been missed, if we had adopted the recommendation to raise the age to start colonoscopy to 35 for subjects with path_MSH6 mutation
Zohar Levi (Israel)

Detection of microsatellite instability using plasma-derived extracellular vesicle DNA – a new perspective for tumor surveillance in Lynch syndrome?
Lena Boohamilitzky (Germany)

Comprehensive molecular profiling of patient-derived tumor organoids uncovers in vitro drug sensitivities of sporadic and hereditary colorectal cancers
Erdogan Pekcan Erkan (Finland)

Clinical Use Scenarios of Breast Cancer Polygenic Risk Score in Women
Peeter Padrik (Estonia)

Nous-209 genetic vaccine encoding shared cancer neoantigens has demonstrated safety and robust immunogenicity in patients with Microsatellite Instable Tumors and is under evaluation in Lynch syndrome carriers
Elisa Scarselli (Italy)

13:30-14:30

Lunch

14:30-16:30

EHTG-ESCP international Surgery Day “iSTOIC”
See page 30-31 for details
Scientific Program

Day 2 – Saturday, September 30th

14:30-16:30  Parallel Working Groups 7-9

14:30-16:30  Group 7 – Genetic Counselling & Management (incl. Lab diagnosis, NA seq, MMR variant interpretation)

Section 1: Lynch syndrome - national strategies and registries
Chair: Fiona Lalloo (UK)

The UK-model
Laura Monje-Garcia (UK) 15'

The DK-model
Christina Therkildsen (Denmark) 15'

Section 2: Ethical dilemmas – Risk information in families
Chair: Kaisa Fritzell (Sweden)

Experiences from direct provider-mediated cascade-testing in Lynch syndrome families – the Danish model
Lars Lindberg (Denmark) 8'

Mismatch repair deficiency – extent of investigation and management of “unexplained” cases: UK cancer genetics group national consensus meeting
Terri McVeigh (UK) 8'

Lynch syndrome Super-spreader: Legal, ethical, regulatory and social implications of sperm donors’ genetic screening
Zohar Levi (Israel) 8'

Section 3: Diagnostic tools – dilemmas
Chair: Inge Bernstein (Denmark)

MLH1 promotor hypermethylation in colorectal and endometrial carcinomas from patients with Lynch syndrome
Maartje Nielsen (The Netherlands) 8'

Scientific Program

Day 2 – Saturday, September 30th

An Exploration of the Somatic and Germline Mutational Profiles of Early-Onset Colorectal Cancer Based on Two UK Patient Cohorts
Penelope Edwards (UK) 8'

Challenging interpretation of germline TP53 variants
Henriett Butz (Hungary) 8'

Section 4: Posters – Two minutes pitch + 1 slide
Chair: Inge Bernstein (Denmark)

Prevalence of CHEK2-Pathogenic/Likely Pathogenic Variant - Positive and Management in Hereditary Breast Cancer Syndrome in Our Centre.
Francisco Javier Jiménez-Ruiz (Spain) 2'

Development and performance of a PMS2-specific NGS product for genetic testing of Lynch syndrome
Jessica De Loma Olson (Sweden) 2'

Enhancing interpretation and classification of POLEand POLD1 variants: Gene-specific recommendations and in vitro functional study system development
Julen Viana (Spain) 2'

RNA-based analyses expand the molecular genetic diagnostic workflow of Lynch syndrome
Vince Kornél Grolmusz (Hungary) 2'

The landscape of Lynch syndrome in the Israeli population
Zohar Levi (Israel) 2'

Summary and Discussion
Fiona Lalloo (UK) 22'
Scientific Program

Day 2 – Saturday, September 30th

14:30-16:30

Group 8 – Gynaecological, urology and other extra-intestinal cancers
Chairs: Emma Crosbie (UK)
Maria Rasmussen (Denmark)
John Burn (UK)

Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors
Maria Rasmussen (Denmark)

ONLY AS VIRTUAL POSTER
Lynch syndrome: Does Hormonal Contraception Protect Against Endometrial Cancer?
Marie Mawet (France)

Highly sensitive microsatellite instability assessment in minimally invasive gynaecological samples allows detection of mismatch repair-deficient endometrial cancer
Julia Canet (Spain)

A pilot study using the Newcastle MSI-Plus assay as a “urine liquid biopsy” in patients with upper tract urothelial cancers and in asymptomatic MSH2 Lynch syndrome carriers.
Rebecca Hall (UK)

Outcomes of Lynch syndrome endometrial cancer surveillance in a nation-wide cohort
Anja Wagner (The Netherlands)

MSI detection of MMR deficient endometrial tumours is influenced by assay sensitivity and MMR gene affected
Michael Jackson (UK)

Breast magnetic resonance screening for BRCA and non-BRCA pathogenic variant carriers
Mev Dominguez Valentin (Norway)

Home-based urine sampling for endometrial cancer detection in Lynch syndrome
Jean-Ellen Johnson (UK)

A Mismatch in Guidelines for Lynch syndrome: A Systematic Review & Meta-Analysis
Neil Ryan (UK)

16:30-17:00
Coffee Break

Scientific Program

Day 2 – Saturday, September 30th

14:30-16:30

Group 9 – Immunology and Pathology
Chairs: Shizuko Sei (USA)
Vinaya Gunasri (UK)
Aysel Ahadova (Germany)

CAPIT Center for LNP RNA Cancer Immunoprevention
Steve Lipkin (USA)

Relationship between neoantigen load and the T cell response in mismatch-repair deficient / ultramutated POLE-mutant cancers
David Church (UK)

The immune profile of Lynch syndrome-associated colorectal adenomas pinpoints the main determinants of immune activation
Lena Bohaumilitzky (Germany)

Immune evasion is more frequent among prevalent than incident Lynch syndrome colorectal cancers
Aysel Ahadova (Germany)

HLA Type as a possible modulator of cancer risk in Lynch syndrome: first data from the INDICATE Network
Aysel Ahadova (Germany)

Math4INDICATE - Methodological challenges for investigating the influence of the HLA genotype on cancer risk in Lynch syndrome
Saskia Haupt (Germany)

Tumor3D – A platform for virtual 3D tumor models from histology sections
Alexander Zeilmann (Germany)

15’
Discussion
Scientific Program

Day 2 – Saturday, September 30th

17:00-18:45  CMMRD Session
Room Humanitas

15’ CMMRD: the clinical spectrum and differential diagnoses
Katharina Wimmer (Austria)

15’ New guidelines for CMMRD diagnosis, counseling, surveillance, clinical management and quality of life
Crystelle Colas (France)

15’ Gastroenterological surveillance for CMMRD
Mariëtte van Kouwen (The Netherlands)

15’ Place of immune checkpoint therapy in CMMRD
Léa Guerrini-Rousseau (France)

15’ Neuroimaging features of CMMRD syndrome and comparison of brain MRIs of children with high-grade gliomas according to MMR gene mutational status
Volodia Dangouloff-Ros (France)

15’ Update about systemic immunological implications of CMMRD
Matthias Kloor (Germany)

18:30-18:45  CMMRD Speed Talks

5’ A validated highly sensitive microsatellite instability assay accurately identifies biallelic germline PMS2 mutation carriers among Constitutional Mismatch Repair Deficiency individuals.
Marta Pineda (Spain)

5’ Cases of constitutional mismatch repair deficiency mimicking Lynch syndrome caused by hypomorphic variants
Richard Gallon (UK)

5’ Digestive burden of patients with Constitutional MisMatch Repair Deficiency syndrome, diagnostic pitfalls and experience of immunotherapy: a report from the C4CMM RD database.
Crystelle Colas (France)

Scientific Program

Day 2 – Saturday, September 30th

19:30 +  Conference Dinner

Conference Dinner at La Bohème

The Restaurant La Bohème is situated in the Old Town of Vilnius, about 10-15 minutes walking distance from the Panorama Hotel

Šv. Ignoto g. 4/3 01120 Vilnius
www.laboheme.lt
### EHTG-ESCP International Surgery Day “iSTOIC”*

**Day 2 – Saturday, September 30th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs/Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-11:00</td>
<td>IPAA Technical Considerations I</td>
<td>Valerio Celentano (UK) Dieter Hahnloser (Switzerland)</td>
</tr>
<tr>
<td>09:00-09:20</td>
<td>Staging, timing and technical details of IPAA in FAP</td>
<td>Feza Remzi (USA)</td>
</tr>
<tr>
<td>09:20-09:40</td>
<td>What is different for UC-Pouches and FAP-pouches?</td>
<td>Janindra Warsusavitane (UK)</td>
</tr>
<tr>
<td>09:40-10:00</td>
<td>Plenary Discussion</td>
<td></td>
</tr>
<tr>
<td>10:00-10:20</td>
<td>Stoma yes or no for FAP pouches – virtual ileostomy, early stoma closure?</td>
<td>Valerio Celentano (UK)</td>
</tr>
<tr>
<td>10:20-10:40</td>
<td>Appraisal of robotic IPAA – equal or better?</td>
<td>Marcos Gomez Ruiz (Spain)</td>
</tr>
<tr>
<td>10:40-11:00</td>
<td>Plenary Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>Surgery and Genetics</td>
<td>John Burn (UK) Neil Smart (UK)</td>
</tr>
<tr>
<td>11:30-11:50</td>
<td>Crash Course for Surgeons: What you always wanted to know and never dared to ask about hereditary cancer</td>
<td>Heather Hampel (USA)</td>
</tr>
<tr>
<td>11:50-12:10</td>
<td>Collaborative Networks &amp; advancing genomics knowledge for Surgeons</td>
<td>Frank McDermott (UK)</td>
</tr>
<tr>
<td>12:10-12:30</td>
<td>Implementing a nurse led mainstreaming pathway for Lynch syndrome</td>
<td>Emma Jenkins (UK)</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Plenary Discussion</td>
<td></td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>IPAA Technical Considerations II</td>
<td>Narimantas Samalavičius (Lithuania) Feza Remzi (USA)</td>
</tr>
<tr>
<td>14:30-14:50</td>
<td>Is there still a place for hand-assisted IPAA? Worth learning?</td>
<td>Narimantas Samalavičius (Lithuania)</td>
</tr>
<tr>
<td>14:50-15:10</td>
<td>Pouch failure: taTME redo pouch</td>
<td>Antonio Lacy (Spain)</td>
</tr>
<tr>
<td>15:10-15:30</td>
<td>Pouch failure: is continent ileostomy an alternative?</td>
<td>Gabriela Möslein (Germany)</td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>FAP and Desmoids</td>
<td>Matt Kalady (USA)</td>
</tr>
<tr>
<td>15:45-16:00</td>
<td>FAP and Endometriosis – is it an issue?</td>
<td>Hermann Kessler (USA)</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Plenary Discussion</td>
<td></td>
</tr>
</tbody>
</table>

*International Surgical Group of Those Operating on Inherited colorectal Cancer*
Scientific Program
Day 3 – Sunday, October 1st

08:00-09:00  EHTG Business Meeting

09:00-10:00  WG Reporting Back Session and Collaborative Studies
Chairs: Laura Valle (Spain)
        Rolf Sijmons (The Netherlands)
        Ottilie Swinyard (UK)

10:00-10:30  Coffee Break

10:30-11:30  Hot Topics
Chairs: Lone Sunde (Denmark)
        Alessandro Manucci (Italy)
        Lior Katz (Israel)

Colonoscopy interval in Lynch syndrome:
Time to start a clinical trial?
Martina Cavestro (Italy)

FIT for surveillance in Lynch syndrome
Kevin Monahan (UK)

Comprehensive Analysis of Germline Drivers in Endometrial Cancer
Ying Liu (USA)

Confident to mainstream genomic testing in Lynch syndrome?
A competency guide for nurses.
Siobhan John (UK)

11:30-12:30  Networking with patients representatives and organizations
Chairs: Kelly Kohut (UK)
        Simone Widhalm (Germany)
        Nicole Reents (Germany)

- Patient presentations about their life experiences
- Priorities for research topics
- Gaps in clinical care and patient resources
- Psychosocial aspect for hereditary cancer patients

12:30-13:00  Pathology and clinical data in childhood in FAP, MAP, JPS, PHTS
Chairs: Katharina Wimmer (Austria)
        Marion Dhoooge (France)
Speaker: Andrew Latchford (UK)

Scientific Program
Day 3 – Sunday, October 1st

13:00-13:30  Lunch

13:30-14:00  Late breaking abstracts session
Chairs: Pål Møller (Norway)
        Henriett Butz (Hungary)

8'+2'
Late abstract 1
Colorectal carcinomas from path_MSH6 carriers display a lower level of microsatellite instability and evoke weaker immune responses
Noah Cornelis Helderman (The Netherlands)

8'+2'
Late abstract 2
Re-classification of two MLH1 variants of uncertain significance using clinical data and functional assays
Jane Hübertz Frederiksen (Denmark)

8'+2'
Late abstract 3
The Benefit of Pancreatic Cancer Surveillance in Carriers of Germline BRCA1/2 Pathogenic Variants
Ido Laish (Israel)

14:00-14:45  Newly emerging technologies
Chairs: Zsofia Stadler (USA)
        Ellis Eikenboom (The Netherlands)
        Marta Pineda (Spain)

Liquid biopsy in CRC for early detection and therapy monitoring based on whole genome sequencing data
Ariane Hallermayr (Germany)

MMR functional analysis in diagnostics: the INVUSE project
Tjakko J. van Ham (The Netherlands)

Implementing RAMAN spectroscopy in screening for Lynch patients
Dean Harris (UK)

14:45-15:00  Farewell
Ahadova, Aysel
p. 10, 27
Heidelberg University Hospital
Heidelberg, Germany

Al Maliki, Husam
p. 16
Sussex Medical School
Brighton, United Kingdom

Andini, Katarina
p. 21
UMCG - University Medical Centre Groningen
Groningen, The Netherlands

Arber, Nadir
p. 23
Sourasky Medical Center
Tel-Aviv, Israel

Backman, Ann-Sofie
p. 10
Karolinska University Hospital
Stockholm, Sweden

Bajwa-ten Broeke, Sanne
p. 10
UMCG - University Medical Centre Groningen
Groningen, The Netherlands

Bauerfeind, Peter
p. 16
Hirslanden Clinic St. Anna
Zürich, Switzerland

Bernstein, Inge
p. 24, 25
Aalborg University Hospital
Aalborg, Denmark

Bisseling, Tanya
p. 11, 13, 16
Radboud University Medical Center
Nijmegen, The Netherlands

Bohaumilitzky, Lena
p. 10, 12, 23
Heidelberg University Hospital
Heidelberg, Germany

Buchanan, Dan
p. 16
University of Melbourne
Melbourne, Australia

Burn, John
p. 26, 30
Newcastle University
Newcastle upon Tyne, United Kingdom

Butz, Henriett
p. 25, 33
National Institute of Oncology
Department of Molecular Genetics
Budapest, Hungary

Cambell-Kelly, Melissa
p. 20
Norfolk and Norwich University Hospitals NHS Foundation Trust
Norwich, United Kingdom

Canet-Hermida, Julia
p. 26
Catalan Institute of Oncology (IDIBELL)
Hospitalet de Llobregat, Spain

Capella, Gabriel
p. 12
Catalan Institute of Oncology (IDIBELL)
Hospitalet de Llobregat, Spain

Cavestro, Martina
p. 11, 16, 22, 32
IRCCS San Raffaele Scientific Institute
Milan, Italy

Celentano, Valerio
p. 30
Chelsea and Westminster Hospital
NHS Foundation Trust
London, United Kingdom

Chen-Shtoyerman, Rakefet
p. 21
Ariel University
Ariel, Israel

Church, David
p. 23
University of Oxford
Oxford, United Kingdom

Colas, Crystelle
p. 28
Institut Curie
Paris, France

Crosbie, Emma
p. 22, 26
Manchester University
NHS Foundation Trust
Manchester, United Kingdom

Dangouloff-Ros, Volodia
p. 28
Necker University Hospital
Paris, France

Darbyshire, Mandy
p. 20
Manchester University
NHS Foundation Trust
Manchester, United Kingdom

De Loma Olson, Jessica
p. 25
Devyser AB
Hägersten, Sweden

de Voer, Richarda
p. 18
Radboud University Medical Center
Nijmegen, The Netherlands

Dhooge, Marion
p. 32
Hopital Cochin
Paris, France

Diez de los Tios, Celia
p. 14
University of Navarra
Madrid, Spain

Dominguez Valentin, Mev
p. 12, 15, 20, 21, 26
Oslo University Hospital
Oslo, Norway

Edwards, Penelope
p. 13, 20, 25
St. Marks Hospital
London, United Kingdom

Eijkenboom, Ellis
p. 11, 33
Erasmus MC Cancer Institute
Rotterdam, The Netherlands

Erkan, Pekcan
p. 12, 23
Tampere University and TAYS Cancer Centre
Tampere, Finland

Frank, Alexander
p. 16
Karolinska University Hospital
Stockholm, Sweden
Faculty

Fritzell, Kaisa
Karolinska University Hospital
Stockholm, Sweden
p. 24

Fruscio, Robert
Università degli Studi di Milano-Bicocca
Milan, Italy
p. 11

Gallon, Richard
Newcastle University
Newcastle upon Tyne
United Kingdom
p. 11, 28

Georgiou, Demetra
Imperial and North West London Healthcare
London, United Kingdom
p. 10

Goldberg, Yael
Rabin Medical Center
Petach Tikva, Israel
p. 11

Gomez Ruiz, Marcos
Hospital Universitario Marques de Valdecilla
Santander, Spain
p. 30

Grolmusz, Vince Kornél
National Institute of Oncology
Budapest, Hungary
p. 25

Guerrini-Rousseau, Léa
Université Paris-Saclay
Villeviu, France
p. 28

Gunasri, Vinaya
University College London
London, United Kingdom
p. 27

Hahnloser, Dieter
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
p. 30

Half, Elizabeth
Rambam Health Care Campus
Haifa, Israel
p. 11, 17

Hall, Rebecca
Newcastle University
Newcastle upon Tyne
United Kingdom
p. 26

Hallermayr, Ariane
MGZ Medical Center of Genetics
Munich, Germany
p. 33

Hampel, Heather
Ohio State University
Columbus OH, USA
p. 11, 20, 30

Haraldsdottir, Sigurdis
Landspitali University Hospital
Reykjavik, Iceland
p. 20

Harris, Dean
Swansea University
Swansea, United Kingdom
p. 33

Hasnis, Erez
Rambam Health Care Campus
Haifa, Israel
p. 17

Heidelberg University and Heidelberg Institute for Theoretical Studies (HITS)
Heidelberg, Germany
p. 18, 27

Helderman, Noah Cornelis
LUMC Leiden University Medical Center
Leiden, The Netherlands
p. 19, 33

Hodan, Rachel
Stanford University
Palo Alto, USA
p. 11

Hokkanen, Kalle
Tampere University and TAYS Cancer Centre
Tampere, Finland
p. 18

Hübertz-Frederiksen, Jane
Copenhagen University Hospital, Copenhagen, Denmark
p. 12, 33

Jackson, Michael
Newcastle University
Newcastle upon Tyne
United Kingdom
p. 26

Jelsig, Anne Marie
Rigshospitalet
Copenhagen, Denmark
p. 12, 21, 19

Jenkins, Emma
South Devon Healthcare NHS Foundation Trust
Torquay, United Kingdom
p. 30

Jiménez-Ruiz, Francisco Javier
Hospital Universitario Juan Ramón Jiménez
Huelva, Spain
p. 25

John, Siobhan
Royal United Hospital Bath, United Kingdom
p. 32

Johnson, Jean-Ellen
Manchester University NHS Foundation Trust
Manchester, United Kingdom
p. 26

Jokela, Tiina
University of Jyväskylä
Jyväskylä, Finland
p. 13, 18

Kalady, Matt
Ohio State University
Columbus OH, USA
p. 31

Katz, Lior
Hadassah Medical Center
Jerusalem, Israel
p. 32

Kessler, Hermann
Cleveland Clinic
Cleveland, Ohio, USA
p. 31

Kloor, Matthias
Heidelberg University Hospital
Heidelberg, Germany
p. 10, 18, 28
<table>
<thead>
<tr>
<th>Faculty</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kohut, Kelly</td>
<td>Moeslein, Gabriela</td>
</tr>
<tr>
<td>St George’s University Hospitals</td>
<td>Evangelic Bethesda Hospital</td>
</tr>
<tr>
<td>NHS Foundation Trust</td>
<td>Duisburg, Germany</td>
</tr>
<tr>
<td>London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Koziel, Anna</td>
<td>Möller, Pål</td>
</tr>
<tr>
<td>London North West University</td>
<td>The Norwegian Radium Hospital</td>
</tr>
<tr>
<td>Healthcare NHS Trust</td>
<td>Oslo, Norway</td>
</tr>
<tr>
<td>London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Lacy, Antonio</td>
<td>Monahan, Kevin</td>
</tr>
<tr>
<td>Clinica Rotger</td>
<td>St. Marks Hospital</td>
</tr>
<tr>
<td>Barcelona, Spain</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Laish, Ido</td>
<td>Monje-Garcia, Laura</td>
</tr>
<tr>
<td>Sheba Medical Center</td>
<td>London North West University</td>
</tr>
<tr>
<td>Ramat Gan, Israel</td>
<td>Healthcare NHS Trust</td>
</tr>
<tr>
<td>p. 33</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Lalloo, Fiona</td>
<td>Moschini, Marco</td>
</tr>
<tr>
<td>Manchester Centre for genomic Medicine</td>
<td>San Raffaele Hospital</td>
</tr>
<tr>
<td>Manchester, United Kingdom</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Latchford, Andrew R.</td>
<td>Nielsen, Maartje</td>
</tr>
<tr>
<td>St. Marks Hospital</td>
<td>LUMC Leiden University Medical Centre</td>
</tr>
<tr>
<td>London, United Kingdom</td>
<td>Leiden, The Netherlands</td>
</tr>
<tr>
<td>Levi, Zohar</td>
<td>Nordstroem, Ulla</td>
</tr>
<tr>
<td>Clinica Rotger</td>
<td>Rigshospitalet</td>
</tr>
<tr>
<td>Rabin Medical Center</td>
<td>Copenhagen, Denmark</td>
</tr>
<tr>
<td>Petach Tikva, Israel</td>
<td>Tartu University Hospital</td>
</tr>
<tr>
<td>Lindberg, Lars</td>
<td>Tartu, Estonia</td>
</tr>
<tr>
<td>Copenhagen University Hospital</td>
<td>Università degli Studi dalla</td>
</tr>
<tr>
<td>Hvidovre, Denmark</td>
<td>Campania „Luigi Vanvitelli”</td>
</tr>
<tr>
<td>Lipkin, Steve</td>
<td>Naples, Italy</td>
</tr>
<tr>
<td>Weill Cornell Medicine</td>
<td>Pineda, Marta</td>
</tr>
<tr>
<td>New York, USA</td>
<td>Catalan Institute of Oncology</td>
</tr>
<tr>
<td>Liu, Ying</td>
<td>(IDIBELL)</td>
</tr>
<tr>
<td>Memorial Sloan Kettering</td>
<td>Hospital de Llobregat, Spain</td>
</tr>
<tr>
<td>Cancer Center</td>
<td>San Raffaele Hospital</td>
</tr>
<tr>
<td>New York, USA</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Loughrey, Mechelle</td>
<td>Puzzono, Marta</td>
</tr>
<tr>
<td>St. Vincent’s University Hospital</td>
<td>San Raffaele Hospital</td>
</tr>
<tr>
<td>Dublin, Ireland</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>Lubinski, Jan</td>
<td>Rafnsdóttir, Ásthildur</td>
</tr>
<tr>
<td>Pomeranian Medical University</td>
<td>Landspitali University Hospital</td>
</tr>
<tr>
<td>Szczecin, Poland</td>
<td>Reykjavik, Iceland</td>
</tr>
<tr>
<td>Mäki-Nevala, Satu</td>
<td>Copenhagen University Hospital</td>
</tr>
<tr>
<td>University of Helsinki</td>
<td>Hvidovre, Denmark</td>
</tr>
<tr>
<td>Helsinki, Finland</td>
<td></td>
</tr>
<tr>
<td>Manucci, Alessandro</td>
<td>Reents, Nicole</td>
</tr>
<tr>
<td>San Raffaele Hospital</td>
<td>SemiColon Germany</td>
</tr>
<tr>
<td>Milan, Italy</td>
<td>Mönchengladbach, Germany</td>
</tr>
<tr>
<td>Mawet, Marie</td>
<td>Remzi, Feza</td>
</tr>
<tr>
<td>Hopital Tenon</td>
<td>NYU Langone Inflammatory Bowel</td>
</tr>
<tr>
<td>Paris, France</td>
<td>Disease Center</td>
</tr>
<tr>
<td>McDermott, Frank</td>
<td>New York, USA</td>
</tr>
<tr>
<td>Royal Devon University</td>
<td>University of Edinburgh</td>
</tr>
<tr>
<td>Healthcare Trust</td>
<td>Edinburgh, United Kingdom</td>
</tr>
<tr>
<td>Exeter, Ireland</td>
<td></td>
</tr>
<tr>
<td>McVeigh, Terri</td>
<td>Samalavicius, Narimantas</td>
</tr>
<tr>
<td>Royal Marsden NHS</td>
<td>Klaipeda University Hospital</td>
</tr>
<tr>
<td>Foundation Trust</td>
<td>Klaipeda, Lithuania</td>
</tr>
<tr>
<td>London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
Faculty

Sanctorum, Katlijn
p. 12, 19

Sanderson, Amy
p. 19

Sayyed, Raza
p. 20

Scarselli, Elisa
p. 23

Sei, Shizuko
p. 10, 27

Shiu, Kai-Keen
p. 23

Sei, Shizuko
p. 18

Sijmons, Rolf
p. 32

Sinicrope, Frank A.
p. 10, 23

Smart, Neil
p. 30

Stadler, Zsofia
p. 20, 33

Sunde, Lone
p. 32

Swinyard, Ottilie
p. 10, 18, 32

Terlouw, Diantha
p. 13, 17

Terradas, Mariona
p. 19

Therkildsen, Christina
p. 24

Thomas, Laura
p. 17, 18

FAPA
Brussels, Belgium

Sheffield Teaching Hospitals
Sheffield, United Kingdom

Patel Hospital
Karachi, Pakistan

Nouscom Srl
Rome, Italy

National Cancer Institute
Maryland, USA

UCL Cancer Institute
London, United Kingdom

University of Jyväskylä
Jyväskylä, Finland

University Medical Centre
Groningen
Groningen, The Netherlands

Mayo Clinic
Rochester, USA

Royal Devon & Exeter Hospital
Exeter, United Kingdom

Memorial Sloan Kettering
Cancer Center
New York, USA

Aalborg University Hospital
Aalborg, Denmark

Barts Cancer Institute
London, United Kingdom

LUMC Leiden University
Medical Centre
Leiden, The Netherlands

Catalan Institute of Oncology
(IDIBELL)
Hospitalet de Llobregat, Spain

Copenhagen University Hospital
Hvidovre, Denmark

Swansea University
Swansea, United Kingdom

Faculty

Valle, Laura
p. 12, 19, 32

van Ham, Tjakko
p. 33

van Enckevort, Esther
p. 11

van Kouwen, Mariëtte
p. 28

Varde, Avani
p. 17

Viana-Erroasti, Julen
p. 24

Wagner, Anja
p. 11, 12, 26

Walton Bernstedt, Sophie
p. 17

Warsusavitarne, Janindra
p. 30

Widhalm, Simone
p. 19, 32

Wimmer, Katharina
p. 28, 32

Young, Julie
p. 19

Zaffaroni, Gloria
p. 11

Zeilmann, Alexander
p. 18, 27

Catalan Institute of Oncology
(IDIBELL)
Hospitalet de Llobregat, Spain

Erasmus MC Cancer Institute
Rotterdam, The Netherlands

UMCG
Houten, The Netherlands

Radboud University Medical Center
Nijmegen, The Netherlands

Imperial College London
London, United Kingdom

Catalan Institute of Oncology
(IDIBELL)
Hospitalet de Llobregat, Spain

St. Mark’s Hospital
London, United Kingdom

Semi-Colon
Düsseldorf, Germany

Medical University of Innsbruck
Innsbruck, Austria

Patient representative
Southampton, United Kingdom

Evangelic Bethesda Hospital
Duisburg, Germany/Italy

Heidelberg University and
Heidelberg Institute for Theoretical
Studies (HITS)
Heidelberg, Germany
Sponsors

The event is sponsored by the following companies or institutions:

Dvysr
www.devyser.com 3.000 EUR

LS CancerDiag
www.lscancerdiag.com 3.000 EUR

Ovesco
www.ovesco.com 1.000 EUR

Imprint

Responsible in accordance with press law:
Prof Dr med Gabriela Moeslein
Evangelisches Bethesda Krankenhaus
Zentrum für Hereditäre Tumorerkrankungen
47053 Duisburg
g.moeslein@bethesda.de

Organisation:
EHTG secretariat and
MCE – Medical Congresses & Events e.K.:
Gabriele Sponholz, gs007@ehtg.org / gs@mce.info